0001209191-21-006328.txt : 20210129
0001209191-21-006328.hdr.sgml : 20210129
20210129201711
ACCESSION NUMBER: 0001209191-21-006328
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210127
FILED AS OF DATE: 20210129
DATE AS OF CHANGE: 20210129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clayman Michael D.
CENTRAL INDEX KEY: 0001597407
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36287
FILM NUMBER: 21573782
MAIL ADDRESS:
STREET 1: C/O FLEXION THERAPEUTICS, INC.
STREET 2: 10 MALL ROAD, SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Flexion Therapeutics Inc
CENTRAL INDEX KEY: 0001419600
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
BUSINESS PHONE: (781) 305-7777
MAIL ADDRESS:
STREET 1: 10 MALL ROAD
STREET 2: SUITE 301
CITY: BURLINGTON
STATE: MA
ZIP: 01803
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-27
0
0001419600
Flexion Therapeutics Inc
FLXN
0001597407
Clayman Michael D.
C/O FLEXION THERAPEUTICS, INC.
10 MALL ROAD, SUITE 301
BURLINGTON
MA
01803
1
1
0
0
President and CEO
Common Stock
2021-01-27
4
A
0
119500
0.00
A
275677
D
Common Stock
2021-01-28
4
F
0
8776
12.37
D
266901
D
Common Stock
347908
I
By the Michael D.Clayman 2006 Revocable Trust
Common Stock
24600
I
By the Michael D. Clayman Irrevocable Trust
Common Stock
388683
I
By Versant Development Fund III, LLC
On March 2, 2020, the Reporting Person was granted 175,000 restricted stock units. The vesting of the shares under the restricted stock unit award was to be based on the achievement of a specified amount of 2020 revenues from ZILRETTA product sales established at the time of the Compensation Committee's approval of the restricted stock unit award. On January 27, 2021, the Compensation Committee certified the achievement of a specified amount of 2020 revenues from ZILRETTA product sales resulting in the commencement of vesting of 119,500 shares. The remaining 55,500 restricted stock units granted to the Reporting Person on March 2, 2020, were forfeited based on the above performance metrics. The Reporting Person previously reported the restricted stock units in Table II of Form 4.
Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on March 2, 2020.
Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
/s/ Mark S. Levine, Attorney-in-Fact
2021-01-29